Navigation Links
Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Date:12/27/2007

KENILWORTH, N.J., Dec. 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will provide a live audio webcast of an informal presentation by Fred Hassan, chairman and chief executive officer, followed by a question-and-answer session, at the Morgan Stanley Pharmaceutical CEOs Unplugged Conference on Jan. 3, 2008, at approximately 8:45 a.m. (ET). Morgan Stanley hosts will moderate the informal "unplugged" presentation.

Included in Mr. Hassan's comments will be Schering-Plough's strategic evolution and the acquisition of Organon BioSciences N.V. (OBS). During the conference he may confirm that the company is still targeting the same accretion and synergy targets mentioned when the OBS acquisition was announced March 12, 2007, specifically that the transaction is anticipated to be accretive to Schering-Plough's earnings per share by about 10 cents in the first full year, excluding purchase-accounting adjustments and acquisition- related costs; and Schering-Plough expects to achieve annual synergies of $500 million. It is expected to take three years from the closing to reach this level of synergies.

Hassan may also reaffirm the following items as disclosed in previous Securities and Exchange Commission filings:
-- Schering-Plough anticipates that sales from VYTORIN and ZETIA will

continue to grow in the fourth quarter of 2007 and in 2008;

-- Schering-Plough is confident in its key products; however, these

products face growing competition. Schering-Plough will invest in its

key brands to sustain their leadership position;

-- As Schering-Plough's pipeline continues to progress, it expects that

the number of patients in clinical trials will continue to in
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
11. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
(Date:12/19/2014)... December 18, 2014 Today, ... its pilot production facility and future company headquarters ... produce innovative new materials that safely and effectively ... only because of its historic, strong support for ... to attract leading edge, technology-based companies such as ...
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... President, Operations and Chief Financial Officer ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Calif., Nov. 5, 2010 Clarient, Inc. (Nasdaq: ... unanimously agreed to recommend that Clarient stockholders tender their shares ... the previously announced price of $5.00 per share of Clarient,s ... Convertible Preferred Stock. The transaction is expected to ...
Cached Biology Technology:OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 2OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 3OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 4OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 5OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 6OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 7OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 8OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 2Study Shows Cardiovascular Deaths in Europe Could Be Prevented 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 4Study Shows Cardiovascular Deaths in Europe Could Be Prevented 5Study Shows Cardiovascular Deaths in Europe Could Be Prevented 6Study Shows Cardiovascular Deaths in Europe Could Be Prevented 7Study Shows Cardiovascular Deaths in Europe Could Be Prevented 8Study Shows Cardiovascular Deaths in Europe Could Be Prevented 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 10Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 2Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 3Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer 4
(Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... brain development in infants and detect disturbances in white ... of Radiology. , Carola van Pul, Ph.D., and colleagues ... seven normal infants and 10 infants with perinatal hypoxic ... period of oxygen and nutrient deficiency, usually as a ...
... immediate pain of the bite is followed by swelling, ... nausea, blurred vision and possibly convulsions before it's all ... brew of toxins in snake venom. , It's long ... than reducing the symptoms, may make things worse. But ...
... study shows motion and door sensors placed in elders' ... to memory changes that are early signs of dementia. ... 10th International Conference on Alzheimer's Disease and Related Disorders ... activity may be a reliable way of assessing changes ...
Cached Biology News:New tool tracks brain development in babies 2Stanford snake venom study shows that certain cells may eliminate poison 2Stanford snake venom study shows that certain cells may eliminate poison 3Stanford snake venom study shows that certain cells may eliminate poison 4In-home sensors spot dementia signs in elderly 2In-home sensors spot dementia signs in elderly 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: